SCHEMBL16626254

SCHEMBL16626254

Cc1ccccc1-c1ccc2nc(-n3cccn3)nc(N(C)C)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.54
CYP2D6 P10635 7/20 0.54
CYP2C19 P33261 7/20 0.54
CYP3A4 P08684 7/20 0.54
CLK4 Q9HAZ1 6/20 0.54
TSHR P16473 6/20 0.54
MAPK1 P28482 4/20 0.54
ALDH1A1 P00352 4/20 0.54
CYP2C9 P11712 2/20 0.54
EGLN1 Q9GZT9 8/20 0.50
ADORA2A P29274 1/20 0.44
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 3/20 0.41
USP2 O75604 2/20 0.41
NMT2 O60551 1/20 0.41
NMT1 P30419 1/20 0.41
HSD17B10 Q99714 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14992599 0.90 EGLN1 (0.54) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL16626265 0.88 EGLN1 (0.52) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL16626187 0.87 EGLN1 (0.64) CYP1A2CYP2D6CYP3A4CLK4MAPK1
SCHEMBL14992943 0.83 EGLN1 (0.44) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL14993318 0.83 ADORA2A (0.43) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL623113 0.80 EGLN1 (0.79) EGLN1
SCHEMBL16626213 0.80 EGLN1 (0.52) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL16626190 0.79 EGLN1 (0.64) CYP1A2CYP2D6CYP2C19CYP3A4CLK4
SCHEMBL627269 0.79 EGLN1 (0.61) MAPK1CYP2C9EGLN1ADORA2AMAPT
SCHEMBL627572 0.78 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19CYP3A4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 2021-04-13 US disclosed
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-03-26 US disclosed
US-9006251-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARAMCEUTICA NV (BE) 2015-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 CYP1A2 98/4885CYP2D6 442/4885CYP2C19 161/4885
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 CYP1A2 98/4885CYP2D6 442/4885CYP2C19 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.